StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Sangamo Therapeutics's operating margin for the twelve months ending Mar 31, 2026 was -357.5%. For fiscal 2025 it was -306.5%, against -179.9% the year before. The highest annual figure on record is -58.4% in fiscal 2014.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-306.5%−126.7
FY2024Dec 31, 2024-179.9%−24.4
FY2023Dec 31, 2023-155.5%+25.4
FY2022Dec 31, 2022-180.8%−15.2
FY2021Dec 31, 2021-165.6%−56.0
FY2020Dec 31, 2020-109.6%−6.9
FY2019Dec 31, 2019-102.7%−11.3
FY2018Dec 31, 2018-91.4%+62.8
FY2017Dec 31, 2017-154.1%+220.1
FY2016Dec 31, 2016-374.2%−255.7
FY2015Dec 31, 2015-118.5%−60.1
FY2014Dec 31, 2014-58.4%+52.3
FY2013Dec 31, 2013-110.7%−8.2
FY2012Dec 31, 2012-102.5%+244.6
FY2011Dec 31, 2011-347.1%−227.3
FY2010Dec 31, 2010-119.9%−32.4
FY2009Dec 31, 2009-87.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-2215.4%−1755.1
Q4 FY2025Dec 31, 2025-268.5%+75.7
Q3 FY2025Sep 30, 2025-6119.3%−6140.8
Q2 FY2025Jun 30, 2025-97.5%+10319.3
Q1 FY2025Mar 31, 2025-460.3%+10252.0
Q4 FY2024Dec 31, 2024-344.2%+2694.9
Q3 FY2024Sep 30, 202421.5%+1153.8
Q2 FY2024Jun 30, 2024-10416.9%−8608.9
Q1 FY2024Mar 31, 2024-10712.3%−10723.7
Q4 FY2023Dec 31, 2023-3039.1%−2835.7
Q3 FY2023Sep 30, 2023-1132.2%−924.8
Q2 FY2023Jun 30, 2023-1807.9%−1652.3
Q1 FY2023Mar 31, 202311.4%+171.7
Q4 FY2022Dec 31, 2022-203.4%−60.9
Q3 FY2022Sep 30, 2022-207.5%−37.9
Q2 FY2022Jun 30, 2022-155.7%+19.1
Q1 FY2022Mar 31, 2022-160.3%+15.9
Q4 FY2021Dec 31, 2021-142.6%+25.8
Q3 FY2021Sep 30, 2021-169.6%−163.2
Q2 FY2021Jun 30, 2021-174.7%+1.1
Q1 FY2021Mar 31, 2021-176.2%+164.3
Q4 FY2020Dec 31, 2020-168.3%−171.0
Q3 FY2020Sep 30, 2020-6.4%+126.8
Q2 FY2020Jun 30, 2020-175.8%+15.1
Q1 FY2020Mar 31, 2020-340.5%+203.4
Q4 FY2019Dec 31, 20192.7%+80.1
Q3 FY2019Sep 30, 2019-133.2%−64.3
Q2 FY2019Jun 30, 2019-190.9%−101.6
Q1 FY2019Mar 31, 2019-543.9%−377.7
Q4 FY2018Dec 31, 2018-77.4%+27.9
Q3 FY2018Sep 30, 2018-68.9%+41.4
Q2 FY2018Jun 30, 2018-89.4%+65.3
Q1 FY2018Mar 31, 2018-166.2%+324.1
Q4 FY2017Dec 31, 2017-105.3%+4.9
Q3 FY2017Sep 30, 2017-110.4%+570.0
Q2 FY2017Jun 30, 2017-154.7%+570.4
Q1 FY2017Mar 31, 2017-490.3%–
Q4 FY2016Dec 31, 2016-110.2%–
Q3 FY2016Sep 30, 2016-680.3%–
Q2 FY2016Jun 30, 2016-725.1%–

More Sangamo Therapeutics figures

See a number that looks wrong?